Original research article BACKGROUND: Cardiogenic shock after acute myocardial infarction is an indication for emergent coronary artery bypass grafting in patients not amenable to percutaneous coronary intervention. Our study aimed to evaluate and identify risk factors for early and long-term outcomes in such patients.
c ardiogenic shock (CS), which is a state of global tissue hypoperfusion resulting from reduced ventricular function, occurs most commonly after acute coronary syndromes that are associated with progressive myocardial necrosis caused by infarct extension. CS has been reported in ≈5% to 8% of patients presenting with ST-segment-elevation myocardial infarction (STEMI) 1,2 and 2.5% of those presenting with non-STEMI (NSTEMI). 3 It is the most common cause of death in patients hospitalized for acute myocardial infarction (AMI). 4 The increasing use of early revascularization strategy has improved in-hospital and long-term survival, regardless of the timing of the development of CS or the age of patients. 2, [5] [6] [7] Although single-vessel disease can be adequately treated with primary percutaneous coronary intervention (PCI) of the infarctrelated artery, more than two thirds of the patients in CS after AMI have multivessel coronary artery disease (CAD), 8, 9 in whom complete revascularization (CR) with multivessel PCI is the recommended first line of treatment. 10 However, emergency coronary artery bypass grafting (CABG) should be strongly considered as a complementary reperfusion strategy to PCI in patients with severe multivessel CAD not amenable to PCI 11 because it can achieve postprocedural and 1-year results similar to those of PCI in such high-risk patients. 12 Despite the improvement in outcomes of emergency CABG, the early mortality still remains appreciably high (21%-52%), 2, [13] [14] [15] especially within the first 48 hours after surgery. 16 There is an obvious paucity of publications in the literature that report long-term outcomes or predictors, particularly in patients with CS who survive surgical revascularization. Therefore, we aimed to identify the predictors of early and late mortality after emergency CABG in patients presenting with CS resulting from AMI and to determine how surgical techniques and results have evolved over time.
MethOds data source
A total of 3144 patients with AMI underwent cardiac surgical procedures at the Leipzig Heart Center between January 2000 and June 2014. Of these, 508 consecutive patients who developed CS as a result of pump failure from myocardial dysfunction were included in the present study ( Figure 1 ). Patients who underwent corrective surgery for mechanical complications after AMI and those undergoing concomitant cardiac procedures such as valvular, aortic, or vascular surgery were excluded from the analysis. The preoperative characteristics, clinical profile and medications, intraoperative data, and postoperative outcomes were retrieved from a prospectively entered computerized database. In addition, patient charts were reviewed to confirm the diagnosis and time of onset of CS and to acquire relevant laboratory data.
The study was approved by our university ethics committee. Because this was a retrospective study, individual patient informed consent was waived.
definitions of explanatory Variables
The diagnosis of AMI was made when a rise in cardiac biomarker values (creatine kinase-MB or troponin) with at least 1 value >99th percentile of the upper reference limit was detected in patients with symptoms of ischemia, new significant ST-segment/T-wave changes, new left bundle-branch block, or echocardiographic evidence of new regional wall motion abnormality. 17 Presence of CS, which was prospectively entered into our database for every patient at the time of surgery, was defined as a systolic blood pressure <90 mm Hg for at least 30 minutes with a severe reduction in cardiac index (<1.8 L·min −1 ·m −2 without support or <2.0-2.2 L·min −1 ·m −2 with support) and elevated left or right ventricular (RV) filling pressures; the need for inotropes/intra-aortic balloon pump (IABP)/extracorporeal membrane oxygenation (ECMO) to maintain a systolic blood pressure ≥90 mm Hg; or inadequate clinical Perspective What is new?
• Coronary artery bypass graft surgery plays a limited role in the early management of patients with acute myocardial infarction presenting with cardiogenic shock. It is indicated in patients not amenable to or after unsuccessful percutaneous coronary revascularization. Hence, very few publications report the results of coronary artery bypass grafting in patients developing cardiogenic shock as a result of pump failure after acute myocardial infarction. • Our study not only evaluated the early outcomes and their time-related trends but also revealed longterm outcomes and predictors of late mortality after surgery in this group of patients.
What are the clinical implications?
• The in-hospital mortality, although high for the entire cohort (33.7%), decreased significantly over the study period (42.2% to 24.6%) and is comparable to, if not lower than, that reported in recent literature for patients with cardiogenic shock requiring multivessel percutaneous coronary intervention. Advances in surgical techniques, mechanical assist devices, anesthesia management, and perioperative care, in addition to the higher rate of complete revascularization, are some factors responsible for the improved outcomes. • Although only a third of patients were alive at 10 years, outcomes in hospital survivors were much higher and acceptable (≈50%). One can therefore anticipate superior long-term survival in patients who underwent surgery recently. • Thus, coronary artery bypass grafting is a good alternative to percutaneous coronary intervention in patients with multivessel coronary artery disease presenting with acute myocardial infarction in cardiogenic shock.
peripheral or end-organ perfusion (pH <7.3, serum lactate >2 mmol/L, cool extremities, urine output <30 mL/h, altered mental status), acute pulmonary congestion, or edema; and a heart rate >90 bpm or the need for cardiopulmonary resuscitation. 18, 19 The preoperative lactate level reported is the latest one before CABG because it corroborates the circulatory status of the patient at the start of the operation.
time cohorts
Because the study spans a 15-year period, several factors such as anesthetic management, surgical techniques and equipment/instrumentation, and postoperative care that evolve over time and have a profound impact on early and longterm outcomes are often not accounted for in such analyses. Therefore, we assessed the effect of time on patient outcomes as a surrogate marker for the aforementioned factors and cre- 
Management strategy
Of the total of 508 patients, 221 patients (43.6%) were already in CS on arrival, whereas 285 patients (56.2%) developed CS during the hospital stay. Patients with AMI in CS referred to our department most often have a coronary anatomy not amenable to PCI or less commonly have undergone a complicated or failed PCI. These patients undergo CABG in the next available operating room regardless of the presence or absence of or the time duration after discontinuation of P2Y 12 inhibitor therapy. Patients in low cardiac output despite high-dose inotropic medication receive IABP implantation preoperatively. Preoperative ECMO implantation is reserved for patients with intractable CS or those who develop cardiac arrest. Although the operating surgeon determines the surgical technique and conduit preference, our group most commonly favors off-pump CABG in hemodynamically stable patients and beating-heart on-pump CABG (without aortic clamping) in unstable patients. Total arterial revascularization is performed infrequently in such patients and is reserved only for very young patients (<65 years) who have adequate hemodynamic stability. All patients in whom bleeding is not a concern receive intravenous acetylsalicylic acid ≈6 hours after surgery. P2Y 12 inhibitors are administered from the first postoperative day, preferably for a period of 12 months.
Postoperative Outcomes
In-hospital mortality (HM), defined as mortality occurring within the hospital stay of the patient regardless of the number of postoperative days, was the primary outcome of this study. Late mortality was the secondary outcome. Follow-up was obtained by personal or phone contact with patients and family members and mailed questionnaires, with supplemental information supplied by family physicians and referring cardiologists. The closing interval, that is, the time period during which all surviving patients included in the analysis were exclusively followed up for the present study, was October 2014 through 
data analysis
All statistical analyses were performed with SPSS 17.0 (SPSS Inc, Chicago, IL). Categorical variables are expressed as frequencies and percentages and were compared by use of the χ 2 or Fisher exact test. Continuous variables are expressed as mean±SD and compared by unpaired Student t test or 1-way ANOVA. Furthermore, contingency table analysis was used to evaluate changes with time in the prevalence of preoperative risk factors, intraoperative events, and operative outcomes instead of building a complex model to assess the temporal trends. Of 27 preoperative variables, those that had a univariable value of P<0.25 (age, diabetes mellitus, hyperlipidemia, chronic obstructive pulmonary disease, peripheral vascular disease, left ventricular ejection fraction, New York Heart Association class, use of P2Y 12 inhibitors, timing of CS, resuscitation, ventilation, dose-dependent inotropic support, ECMO, serum lactate >4 mmol/L, and prior cardiac surgery) or those that were considered to be clinically relevant were submitted to a logistic regression model by stepwise selection to determine the independent predictors of HM for the whole cohort, which are expressed as odds ratios (ORs) and 95% confidence intervals (CIs). RV function, which was available in only 333 patients (65.6%) in the entire cohort, was not included in the model because data were missing in a third of the patients. In addition, the 2000 to 2004 and 2005 to 2009 time cohorts were forced into the multivariate model, with 2010 to 2014 as the reference, to evaluate the impact of temporal changes in unaccountable factors on HM. Moreover, stepwise logistic regression was performed separately for each time cohort to evaluate the changes in predictors for death over the 15-year period. Multicollinearity was assessed with linear regression analysis, in which a variance inflation factor >4.0 indicated potential intercorrelation among variables. If multicollinearity existed, either correlated variables were combined into a single variable or 1 variable from a set of correlated variables was selected for the multivariate analysis. Model discrimination was Figure 1 . study population flowchart.
AMI indicates acute myocardial infarction; CABG, coronary artery bypass grafting; and CS, cardiogenic shock. assessed by the area under the receiver-operating characteristic curve and calibration by the Hosmer-Lemeshow goodness-of-fit statistic. Long-term survival for the whole cohort and for hospital survivors was calculated by Kaplan-Meier methods with 95% CIs. To provide more robustness to our survival analysis, the survival curve was reconstructed after patients lost to follow-up within 1 year after surgery were labeled as dead because the majority (31 of 49) were lost to follow-up within 1 year after CABG. Independent predictors of long-term survival were determined with Cox proportional hazards analysis. Covariates were included on the basis of clinical relevance or significance of univariable association. Model assessment was performed by calculation of the likelihood χ 2 statistic by comparing the deviance (-2 times log likelihood) of our model, with all of the specified covariates, against the model with all covariates dropped. Values of P<0.05 were considered statistically significant. Table 1 . The number of patients undergoing surgery for CS reduced progressively throughout the study period; however, the proportion of patients in CS on arrival to the hospital was the highest in the most recent time cohort. Although obesity was the only cardiac risk factor that was significantly higher in the 2010 to 2014 cohort patients, a similar trend was observed with regard to age, female sex, systemic hypertension, and hyperlipidemia. The 2010 to 2014 cohort patients also had a significantly greater prevalence of pulmonary hypertension and need for preoperative moderate-to high-dose inotropic support, which correlated well with the fact that this cohort also had the largest percentage of patients in New York Heart Association classes III through IV. Comorbidities such as chronic obstructive pulmonary disease, renal and neurological dysfunction, and diabetes mellitus were more commonly detected in 2005 to 2009 cohort patients. Although not significant, the mean serum lactate levels and the proportion of patients with lactate levels >4 mmol/L were the highest in the 2000 to 2004 cohort patients. The use of P2Y 12 inhibitors increased significantly over the years. From the data available in 333 patients, 202 patients (60.7%) had good/normal RV function, whereas 97 (29.1%) and 34 (10.2%) patients had moderately or severely reduced RV function, respectively.
intraoperative data
The intraoperative details are listed in Table 2 . The use of off-pump CABG increased continuously through the study period with a decline in on-pump CABG with cardioplegic arrest. On-pump beating heart surgery, however, continued to be the commonest technique used during the 3 time cohorts. Although the fewest grafts were used in the most recent time cohort, there was no difference in the number of distal anastomoses between cohorts, with a higher proportion of left internal thoracic artery-left anterior descending artery grafts in the last decade and the lowest rate of incomplete revascularization in the last time cohort.
Postoperative Outcomes
The prevalence of immediate postoperative complications and other parameters is given in Table 3 . The overall HM among patients with AMI in CS undergoing isolated emergency CABG was 33.7% but showed a significant decline from 42.2% in the earliest cohort to 24.6% in the most recent one. The fraction of patients with low cardiac output rose significantly over the years with a corresponding increase in IABP and ECMO support. Similarly, transfusion of blood products, respiratory insufficiency, and tracheostomy rates also increased. However, duration of ventilation, number of reintubations, and lengths of intensive care unit and hospital stay were lowest in the most recent time cohort.
Predictors of hM
Stepwise multivariate logistic regression analysis of all 508 patients undergoing isolated emergency CABG identified preoperative serum lactate >4 mmol/L, STE-MI, age >75 years, and left ventricular ejection fraction <30% as significant independent predictors of HM (Table 4 ). Serum lactate >4 mmol/L presented the greatest operative risk, but other markers of critical preoperative state such as preoperative resuscitation (OR, 1.16; 95% CI, 0.69-1.9; P=0.57) and high-dose inotropic support (OR, 1.4; 95% CI, 0.89-2.21; P=0.15) did not independently predict HM, although they were significantly correlated with HM on univariate analysis (P=0.02 and P<0.0001, respectively). As anticipated, the earliest time cohort was also an independent risk factor for HM. Good left ventricular function was found to be protective. Other factors considered clinically relevant were further analyzed. The timing of development of CS, whether before or after admission to our institution, was not an independent predictor of HM, although the latter was associated with a significantly higher HM than the former on univariate analysis (31.5% versus 34.4%; P=0.04). Patients undergoing postoperative IABP implantation were at an increased risk of death compared with those who received preoperative IABP insertion (44.8% versus 30.4%; P=0.004). HM was significantly higher in patients with severely reduced RV function compared with those with moderately reduced 
Follow-up
The 5-and 10-year survival rates for all patients were 42.6±2.0% and 33.4±2.0% (Figure 2A ) and for hospital survivors were 64.3±3.0% and 49.8±3.0%, respectively ( Figure 2B ). Some studies have revealed that the major difference in survival in patients with and without CS usually occurs within the first year after discharge from the hospital. 20, 21 Therefore, reconstruction of the survival curve for our patients, assuming those lost to follow-up within 1 year after surgery as dead, revealed 5-and 10-year Values are expressed as mean±SD when appropriate. CCS indicates Canadian Cardiovascular Society; COPD, chronic obstructive pulmonary disease; CS, cardiogenic shock; ECMO, extracorporeal membrane oxygenation; IABP, intra-aortic balloon pump; LVEF, left ventricular ejection fraction; NSTEMI, non-ST-segment-elevation myocardial infarction; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; and STEMI, ST-segmentelevation myocardial infarction. Figure I) . When survival was stratified by the preoperative serum lactate level (≤4 and >4 mmol/L), the 5-and 10-year survival rates were 49.0±3.0% and 37.7±3.0% and 20.9±4.0% and 13.2±4.0%, respectively (log-rank P<0.001; Figure 3 ). A total of 145 patients died during follow-up. Cox regression analysis including the entire patient cohort revealed preoperative ECMO implantation, serum lactate >4 mmol/L, diabetes mellitus, New York Heart Association class IV, and incremental age as independent predictors of late mortality ( Table 5 ). Left internal thoracic artery-left anterior descending artery grafting and good left ventricular function were found to be protective. However, an analysis of hospital survivors identified preoperative serum lactate >4 mmol/L, inotropic support, and incremental age as factors that increased the risk of late death (Table 5 ).
discussiOn
The SHOCK trial (Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock) was the first prospective, randomized study to unequivocally demonstrate a significant reduction in 6-month mortality with emergent revascularization compared with conservative management in patients with CS after AMI, despite the lack of a significant difference in the 30-day mortality. 8 The lack of a significant difference was probably due to the inadequate sample size required to establish the expected benefit predicted at the time of trial design. Furthermore, CABG was associated with a mortality similar to PCI in both the SHOCK trial and registry patients (41% versus 40% and 28% versus 46%, respectively) despite more extensive CAD. 8, 12, 16 The HM for the whole cohort of 508 patients in the present study was 33.7%, which is lower than that seen with PCI in the SHOCK trial and registry. More recent reports from registries have also demonstrated a higher mortality (36% to 49%) with multivessel PCI in patients with CS. 22, 23 The reason could probably be multifactorial. Predominant use of percutaneous balloon coronary angioplasty in the SHOCK trial may have resulted in a higher restenosis rate and recurrent MI. However, comparison of patients undergoing percutaneous balloon coronary angioplasty with those who received stents in the SHOCK trial revealed no difference in mortality. Left ventricular dysfunction due to pump failure appears to be principally responsible for the high mortality observed in such patients. The use of cardiopulmonary bypass during CABG could positively affect left ventricular function by alleviating the volume and thus the workload of the heart, resulting in a reduction in wall stress and inotropic requirement, which decreases oxygen and energy consumption. In addition, cardiopulmonary bypass restores adequate systemic and endorgan perfusion until a completely revascularized heart can adequately support circulation again. Our group has already reported better postoperative outcomes (less inotropic support, lower rate of new MI, atrial fibrillation, acute renal failure, and stroke) with an on-pump beatingheart strategy in patients with CS after AMI. 24 In addition, CABG is more often associated with CR than PCI, especially in patients with multivessel CAD. A meta-analysis of 35 randomized, controlled trials and observational studies including 89 883 patients revealed a significantly higher rate of incomplete revascularization after PCI than after CABG (56% versus 25%; P<0.001). 25 The Manitoba CS registry investigators demonstrated that 94% of patients undergoing CABG for CS after AMI had CR as opposed to only 45% undergoing PCI and found CR to be protective of hospital survival (OR, 0.26; 95% CI, 0.09-0.76; P=0.013 for HM). 26 The initial evidence of the importance of CR in patients with CS was provided by a substudy of the SHOCK trial. 27 CR relieves a larger myocardial area off ischemia, leading to better overall myocardial contractility and cardiac output and reduced inotrope use and energy requirements. In our study, the overall rate of CR was almost 80%, with the highest rate (86%) in the most recent time cohort.
An analysis of temporal trends revealed a progressive decline in HM from 42.2% between 2000 and 2004 to 26.8% between 2010 and 2014 in the present series. Several factors could have contributed to this observation, one being the aforementioned rise in the rate of CR. Serum lactate level >2 mmol/L is usually considered representative of impaired end-organ perfusion and was used as one of the diagnostic criteria for CS in the IABP-SHOCK trial (Intra-Aortic Balloon Pump in Cardiogenic Shock). 28 Hyperlactatemia on admission is strongly associated with hemodynamic instability 29 and prognosticates worse in-hospital outcomes such as higher mortality and larger infarct size, 30 especially in patients with CS. 31 The preoperative serum lactate level for the whole cohort in the present study was 2.9±3.8 mmol/L. It was 32 reported an increased HM in 754 patients with acute decompensated heart failure in whom lactate levels on admission were >3.2 mmol/L. The exact cutoff values for lactate are still unknown. 33 However, in our study, we found preoperative serum lactate levels >4 mmol/L to be the strongest predictors of HM, not only for the whole cohort (Table 4 ) but also for the earliest and most recent time cohorts (online-only Data Supplement Table  I ). High preoperative lactate levels in patients after AMI could be due to either greater myocardial area at risk, leading to severe left ventricular dysfunction and hemodynamic instability, or delayed patient referral for revascularization, which prolongs the period of low cardiac output and CS. The former is not preventable, but the latter can be addressed by improvement in prehospital/ emergency medical services and triaging, early referral, and expeditious revascularization, advocated by our group for patients with NSTEMI. 34 Another factor that could have lowered HM over the years could be the timing of the development of CS. In a study including 6676 conservatively managed patients with AMI, 41% of 444 patients developed CS after 3 to 4 days and had a 30-day mortality of 84% compared with 45% in those developing shock within 48 hours. Delayed shock can develop as a result of recurrent ischemia or reinfarction, which constituted 38% and 20% of patients with late shock compared with 13% and 3% of patients with early shock. 35 Similarly, more than half of the patients operated on during the most recent time cohort in our study presented with CS on arrival compared with those operated in the earlier time cohorts, who predominantly developed CS after admission. In addition, univariate analysis revealed that patients with CS on admission had a significantly lower HM than those who developed CS after admission. This further reinforces the fact that earlier referral and revascularization of patients with AMI, especially those with CS, would improve outcomes in these sick patients. Some other determinants of lower HM in patients operated on between 2010 to 2014 could be the lower prevalence of comorbidities (except peripheral vascular disease) and triple-vessel/left main disease and better left ventricular function than in those operated on earlier. The higher preoperative use of moderate-to high-dose inotropes in the former may have facilitated the preservation of end-organ perfusion and maintenance of lower lactate levels. The increased use of P2Y 12 inhibitors until surgery could have further contributed to a lower mortality in patients operated on in the most recent time cohort. In a study involving early CABG in patients with NSTEMI, our group identified the use of P2Y 12 inhibitors until surgery as an independent predictor of HM, at least in patients without CS. 34 The use of mechanical assist devices may also contribute to better outcomes. The significantly higher use of postoperative ECMO in recent cohorts may have also resulted in reduction of HM. ECMO can be used as a bailout option in patients who cannot be weaned off cardiopulmonary bypass for various reasons such as stunned myocardium after an infarct, the no-reflow phenomenon after revascularization of the infarct-related artery, and the impact of emergency surgery in patients with poor ventricular function and end-organ hypoperfusion. It provides time for myocardial recovery and improves end-organ perfusion, particularly in patients who would have otherwise died immediately after surgery. The use of IABP in patients with CS after AMI is controversial. The IABP-SHOCK trial did not demonstrate mortality benefit or identify significant differences in hemodynamic stabilization, length of intensive care unit stay, lactate levels, dose and duration of catecholamine therapy, and renal function in patients with periprocedural IABP use. 28 However, the major drawbacks of this trial were the predominant postprocedural use of IABP (86.6%) in the treatment group, the 10% crossover rate, the higher rate of implantation of a ventricular assist device in the control group, and the noncategorization of the clinical spectrum of CS. In addition, only 3.3% of patients underwent immediate CABG. In our study, patients operated on between 2005 and 2009 had a significantly higher rate of preoperative IABP use and greater use of beating-heart surgery, which could probably explain the lower levels of preoperative and postoperative serum lactate levels and HM in this cohort compared with the earliest cohort despite the highest prevalence of comorbidities, lower mean left ventricular function, and highest occurrence of CS after admission and mean creatine kinase-MB levels in the former. Preoperative IABP helps expedite the operation off-pump in patients with relatively stable hemodynamics and induces pulsatility during and enables weaning from cardiopulmonary bypass in patients with profound or refractory CS who undergo on-pump CABG by reducing endothelial cell activation and preserving end-organ function. 36 Furthermore, postoperative IABP use was associated with a higher HM than preoperative implantation for the entire patient cohort and was similar to that reported by Ranucci et al 37 (41.5%) . Therefore, IABP implantation postoperatively rather than preoperatively, especially in the presence of profound refractory CS, may be deleterious. Pilarczyk and coworkers 38 also recently reported a statistically significant improvement in mortality for preoperative IABP implantation (OR, 0.27; 95% CI, 0.13-0.6; P<0.001) in a pooled analysis of 5 randomized, controlled trials including only patients undergoing isolated on-pump CABG.
Patients develop RV dysfunction after AMI either primarily as a result of RV MI itself or secondary to a sudden rise in pulmonary artery pressures caused by an acute deterioration of left ventricular function or loss of important septal contribution to RV cardiac output after large anterior or anterolateral MIs. 39 Several studies have demonstrated that RV MI is the main cause of CS in patients with acute inferior wall MI. 40, 41 A study by Jin et al 42 revealed that preoperative RV diastolic dysfunction and inferior MI were the only predictors of the development of hypotension and shock. Furthermore, in patients with good left ventricular function, RV dysfunction becomes even more pronounced after CABG because of the loss of the compensatory enhanced motion resulting from the development of paradoxical motion of the interventricular septum after CABG. In addition, lack of closure of the pericardium at the end of surgery is known to be a contributing factor as a result of unrestricted volume expansion with an associated increase in wall tension that can occur postoperatively. RV infarction is also associated with a higher incidence of ventricular dysrhythmias and atrioventricular conduction block. Therefore, RV dysfunction after AMI results in high early mortality. 43 Univariate analysis of our patients in whom data on RV function were available revealed that HM was almost 1.5-times and 2-fold higher in patients with poor RV function and RV failure, respectively, compared with those with maintained RV function. Because of missing data, further analysis of RV function was not performed. However, other studies not only have reported significantly higher postoperative deaths (18.7% versus 2.3%, P=0.004) in patients with RV dysfunction 44 but also have revealed RV dysfunction to be a strong independent predictor of early and late mortality, especially in patients with associated left ventricular dysfunction. 44, 45 The present study is one of the largest series in the literature reporting the long-term outcomes of isolated CABG in patients with CS after AMI. Slightly more than a quarter of the patients undergoing emergency CABG were alive at 10 years, but this was attributed chiefly to the poor in-hospital survival. In those patients who survived the hospital stay, >78%, 60%, and 40% were alive after 1, 5, and 10 years, respectively. Our results compare favorably with the 1-and 5-year survival (77% and 59%) of 30-day/hospital survivors enrolled in the French 2005 registry of patients with acute STEMI and NSTEMI, although it included a mix of patients managed most commonly with PCI (61%) or conservative therapy (35%) and a minority managed with CABG (4%). 20 Another contemporary series including 6489 patients from the British Cardiovascular Intervention Society database who underwent PCI for CS after AMI revealed a 1-year survival of ≈55% for all patients, including those who died in hospital. This was similar to the 1-year survival of 51.6±2.3% for all patients in our study. However, the 1-year mortality among 30-day survivors was an impressive 11% only. 46 is dismal. However, survival in those who are alive at 30 days is better. Lindholm et al 35 reported a 6-year mortality of 88% and 68% in all conservatively treated patients with shock and 30-day survivors, respectively. Similarly, the long-term data of 1891 patients with shock from the GUSTO-I trial (Global Utilization of Streptokinase and Tissue-Type Plasminogen Activator for Occluded Coronary Arteries) revealed a 27.8% and 55.2% survival for the whole cohort and 30-day survivors, respectively, at a median of 11 years, 47 which was comparable to the overall 10-year survival observed in the present study even when patients lost to follow-up within 1 year of surgery were assumed dead. Certain presumptions can be drawn from the present and the other above-mentioned studies. Late mortality is prohibitively high in studies with either no or very low rates of revascularization. This demands endeavors to alter the natural history of the disease through appropriate interventions. The early and late mortality rates continue to be high in all contemporary series in which modern techniques of revascularization and medications have been used. Nevertheless, HM in the most recent time cohort of patients undergoing CABG in our study is one of the lowest reported so far. Although this could be due to differences in patient populations and the definitions and degree of CS compared with previous reports, we believe that higher rates of CR achieved by CABG (especially in the last cohort), in addition to marked advancements in anesthetic and operative techniques and postoperative care, contribute significantly to better outcomes. Furthermore, we anticipate that the follow-up survival of patients in the most recent time cohort would be higher than for those in the other cohorts, which would also improve the survival of the whole cohort. Our assumption is supported by Gaudino et al, 48 who report an overall survival rate of 64% at a mean follow-up of 78±48 months in patients undergoing CABG for CS. Finally, long-term results in survivors are good, and the highest mortality occurs within the first 6 months to 1 year, regardless of implementation or type of revascularization. This is probably due to the extension of the detrimental effects of activated complements, cytokines, expressed nitric oxide synthase, and other mediators of systemic inflammatory response with the added component of dysfunctional myocardium into the period after hospital discharge. 21 Resolution of these effects can probably explain the complete reversibility of the shock state in some patients, resulting in improved survival after this vulnerable postdischarge period.
Serum lactate >4 mmol/L was the strongest predictor of late mortality not only for all patients but also for hospital survivors. In addition, long-term survival in patients with serum lactate level >4 mmol/L just before surgery was significantly lower than for those with lactate levels ≤4 mmol/L (Figure 3 ). High lactate levels result from impaired end-organ perfusion caused by low cardiac output that is a consequence of left ventricular dysfunction caused by ischemic or infarcted myocardium. The longterm effect of high serum lactate levels shows that it is a surrogate marker for the degree of irreversible myocardial damage, which results in chronically poor left ventricular function. Other predictors of late mortality depicted in Table 5 are the factors that are commonly observed and expected to affect late mortality in most studies.
study limitations
The retrospective nature of the study subjects it to the inherent weaknesses of such analyses. The 3 time cohorts are different with respect to preoperative characteristics of the patients included. However, the chief objective of this study was to analyze these variations over time and to evaluate the impact of these changes on HM, which can be performed only by comparing groups of patients assigned to designated time periods. Whether CABG is the best option to treat all patients with multivessel CAD in CS cannot be determined from this study because there is no control group consisting of patients receiving conservative or interventional therapy. A randomized, controlled trial could resolve this dilemma.
conclusions Emergency CABG in patients with AMI complicated by CS is associated with a high HM, which, however, declined significantly over the study period. Overall long-term survival of patients in CS is discouraging. Nevertheless, hospital survivors have good long-term outcomes, which demonstrate the beneficial effect of surgical revascularization. Preoperative serum lactate >4 mmol/L is a strong predictor of both early and late mortality and is associated with dismal outcomes. Left internal thoracic artery-left anterior descending artery graft positively affect long-term survival even in patients with CS and therefore should be promoted. Use of preoperative IABP in such patients should be encouraged.
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